Journal Article – GLP1-RAs and Thyroid Cancer Risk
January 16, 2025Thyroid Vol 35, No. 1 This research article investigates the potential link between glucagon-like peptide 1 receptor agonists (GLP1-RAs), medications used for type 2 diabetes, and the risk of developing thyroid cancer. Conducted as a large, international study across multiple sites in six countries, it compared GLP1-RA users with those using dipeptidyl peptidase-4 inhibitors (DPP-4is), another class […]
Long‐term delirium and survival outcomes in patients treated with GLP‐1 receptor agonists versus metformin in type 2 diabetes: A population‐based cohort study
Abstract Aim Type 2 diabetes mellitus (T2DM) is associated with an increased risk of delirium and mortality. While glucagon-like peptide-1 receptor agonists (GLP-1 RAs) provide metabolic and neuroprotective benefits, their long-term impact on delirium risk remains uncertain. This study compares GLP-1 RAs and metformin in relation to delirium and mortality in T2DM patients using real-world […]
Containing the Obesity Epidemic
by Carol A Westbrook What is the hardest thing about dieting, the reason that most dieters give up? They get hungry. Wouldn’t it be great if there were a pill that would leave you satisfied after a diet meal without those hunger pangs? A medicine that would keep you on a diet and help you […]
The Federal Perspective on Coverage of Medications to Treat Obesity: Considerations From the Congressional Budget Office
Presentation by Noelia Duchovny, an analyst in CBO’s Health Analysis Division, at the National Institute of Diabetes and Digestive and Kidney Diseases Workshop on GLP-1-Based Therapies.
Judge hands win to FDA, Lilly in tirzepatide shortage case
A federal court handed the FDA and Eli Lilly a major win in a case challenging the end of the tirzepatide shortage. On Wednesday, The US District Court for the Northern District of Texas denied …
Novo Nordisk Predicts Strong Second Half
Here’s our initial take on Novo Nordisk‘s (NYSE: NVO) fiscal 2025 first-quarter financial report. Key Metrics Metric (all figures in Danish kroner) Q1 2024 Q1 2025 Change vs. Expectations Revenue 65.35 billion 78.09 billion 19% Missed Earnings per share 5.68 6.53 15% Beat Operating profit 31.85 billion 38.79 billion 22% n/a Obesity care sales 11.2 […]
Novo’s Wegovy takes a hit from compounders, but company expects faster second-half growth
As the U.S. GLP-1 market is in a period of transition, Novo Nordisk is holding out hope for faster growth in the second half of 2025.